First-pass extracted concept

small interfering RNAs

Candidate: concept label2 source documents5 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

siRNAs

Extracted Explainers

What the tool is doing

The review lists siRNAs as a therapeutic RNA modality considered for multiple myeloma.

Source 1DOI PubMed

What problem it solves

It is framed as part of innovative strategies intended to address unmet need in refractory myeloma.

Source 1DOI PubMed

Evidence Snippets

modalities including mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) mimics/inhibitors

Evidence 1Source 1DOI PubMedprovenance

small interfering RNAs (siRNAs) exhibit greater potency.

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Source 2primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1commercialization barriersupports2026Source 2DOI PubMed

Delayed commercialization of siRNAs may be due to passenger strand-dependent off-target effects and immature design and modification strategies.

Quoted textsource-backed

The delayed commercialization of siRNAs, despite high research interest, may be attributed to passenger stand-dependent off target effect and the immaturity of their design and modification strategies.

Claim 2modality comparisonsupports2026Source 2DOI PubMed

Most approved and clinical-trial oligonucleotide-based gene therapeutics are antisense oligonucleotides even though siRNAs show greater potency in cell culture data.

Quoted textsource-backed

the majority of approved OGTs, as well as those currently in clinical trials, are antisense oligonucleotides (ASOs) despite cell culture data showing that small interfering RNAs (siRNAs) exhibit greater potency.

Claim 3scope of reviewsupports2026Source 1DOI PubMed

The review assesses RNA-based therapeutic modalities for multiple myeloma including mRNA vaccines, siRNAs, ASOs, and miRNA mimics or inhibitors using preclinical and clinical evidence.

Quoted textsource-backed

In this review, we assess cutting-edge RNA-based therapeutics for MM modulation, drawing on preclinical and clinical evidence on modalities including mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) mimics/inhibitors.

Claim 4screening success ratesupports2026Source 2DOI PubMed

Only about 2% of tested siRNAs achieve 70% target gene knockdown in vitro.

Quoted textsource-backed

data suggests that only about 2% of the tested siRNAs achieve the expected 70% target gene knockdown in vitro.

Claim 5therapeutic potentialsupports2026Source 1DOI PubMed

The review concludes that RNA technologies have transformative potential in refractory multiple myeloma to achieve durable remissions, overcome resistance, reduce costs, and enable more personalized and safer treatments.

Quoted textsource-backed

By integrating these insights, we underscore RNA technologies' transformative potential to achieve durable remissions, overcome resistance, and reduce costs-paving the way for personalized, safer treatments in refractory MM.